Which has preferable valuation and earnings, SCPS or ARDS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 0.00

Is SCPS or ARDS more profitable?

Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A

Which has higher valuation and earnings, ARDS or VAXX?

Vaxxinity is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 0.00 Vaxxinity N/A N/A -$56.93M -$0.45 N/A

Is ARDS or VAXX more profitable?

Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Vaxxinity N/A N/A N/A

Is TRVN or ARDS more profitable?

Company Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% Aridis Pharmaceuticals N/A N/A N/A

Is ARDS or NAVB more profitable?

Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A

Is ARDS or SMFL more profitable?

Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Smart for Life N/A N/A N/A

Aridis Pharmaceuticals (ARDS) Competitors

$0.0002 0.00 (0.00%)

As of 06/12/2026 11:08 AM Eastern

Compare

ARDS vs. SCPS, VAXX, TRVN, NAVB, and SMFL

Should you buy Aridis Pharmaceuticals stock or one of its competitors? MarketBeat compares Aridis Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aridis Pharmaceuticals include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), and Smart for Life (SMFL). These companies are all part of the "pharmaceutical products" industry.

How does Aridis Pharmaceuticals compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

In the previous week, Scopus BioPharma had 1 more articles in the media than Aridis Pharmaceuticals. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Aridis Pharmaceuticals. Scopus BioPharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Aridis Pharmaceuticals	Neutral

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Scopus BioPharma has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 44.97, indicating that its stock price is 4,397% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	0.00

Summary

Aridis Pharmaceuticals beats Scopus BioPharma on 3 of the 5 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Vaxxinity?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Vaxxinity is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	0.00
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A

Aridis Pharmaceuticals has a beta of 44.97, indicating that its stock price is 4,397% more volatile than the broader market. Comparatively, Vaxxinity has a beta of -79.33, indicating that its stock price is 8,033% less volatile than the broader market.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 82.9% of Vaxxinity shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 64.1% of Vaxxinity shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Vaxxinity	N/A	N/A	N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Vaxxinity	Neutral

Summary

Aridis Pharmaceuticals beats Vaxxinity on 4 of the 6 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Trevena?

Trevena (NASDAQ:TRVN) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Trevena has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 44.97, meaning that its stock price is 4,397% more volatile than the broader market.

13.6% of Trevena shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
Aridis Pharmaceuticals	N/A	N/A	N/A

In the previous week, Trevena's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Trevena	Neutral
Aridis Pharmaceuticals	Neutral

Aridis Pharmaceuticals has lower revenue, but higher earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	0.00

Summary

Aridis Pharmaceuticals beats Trevena on 6 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	0.00
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Navidea Biopharmaceuticals	N/A	N/A	N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Navidea Biopharmaceuticals	Neutral

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aridis Pharmaceuticals has a beta of 44.97, indicating that its stock price is 4,397% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Summary

Aridis Pharmaceuticals beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Smart for Life?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Smart for Life	Neutral

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 31.7% of Smart for Life shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aridis Pharmaceuticals has a beta of 44.97, suggesting that its share price is 4,397% more volatile than the broader market. Comparatively, Smart for Life has a beta of 14.81, suggesting that its share price is 1,381% more volatile than the broader market.

Smart for Life has higher revenue and earnings than Aridis Pharmaceuticals. Smart for Life is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	0.00
Smart for Life	$11.11M	0.00	-$22.68M	-$14.48	N/A

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Smart for Life	N/A	N/A	N/A

Summary

Smart for Life beats Aridis Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Aridis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDS vs. The Competition

Export

Metric	Aridis Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11K	$936.76M	$6.49B	$12.31B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	0.00	1.45	24.05	24.76
Price / Sales	N/A	129.85	542.61	168.32
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	N/A	7.98	10.69	6.90
Net Income	-$30.37M	-$4.88M	$3.57B	$337.45M
7 Day Performance	N/A	5.66%	1.56%	2.84%
1 Month Performance	N/A	5.57%	2.49%	4.78%
1 Year Performance	N/A	46.87%	26.51%	33.08%

Aridis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	+100.0%	$11K	N/A	0.00	30
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	+33.3%	$25K	N/A	N/A	9	Gap Up
VAXX Vaxxinity	N/A	$0.00 +100.0%	N/A	+0.0%	$25K	N/A	N/A	90	Gap Up High Trading Volume
TRVN Trevena	N/A	$0.01 +1,010.0%	N/A	-99.9%	$11K	$443K	N/A	40	Gap Down
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aridis Pharmaceuticals (ARDS) Competitors

ARDS vs. SCPS, VAXX, TRVN, NAVB, and SMFL

How does Aridis Pharmaceuticals compare to Scopus BioPharma?

Summary

How does Aridis Pharmaceuticals compare to Vaxxinity?

Summary

How does Aridis Pharmaceuticals compare to Trevena?

Summary

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Summary

How does Aridis Pharmaceuticals compare to Smart for Life?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDS vs. The Competition

Aridis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aridis Pharmaceuticals (ARDS) Competitors

ARDS vs. SCPS, VAXX, TRVN, NAVB, and SMFL

How does Aridis Pharmaceuticals compare to Scopus BioPharma?

Does the media favor SCPS or ARDS?

Do insiders & institutionals have more ownership in SCPS or ARDS?

Which has more risk & volatility, SCPS or ARDS?

Is SCPS or ARDS more profitable?

Which has preferable valuation and earnings, SCPS or ARDS?

Summary

How does Aridis Pharmaceuticals compare to Vaxxinity?

Which has higher valuation and earnings, ARDS or VAXX?

Which has more volatility & risk, ARDS or VAXX?

Do institutionals and insiders have more ownership in ARDS or VAXX?

Is ARDS or VAXX more profitable?

Does the media refer more to ARDS or VAXX?

Summary

How does Aridis Pharmaceuticals compare to Trevena?

Which has more volatility & risk, TRVN or ARDS?

Do institutionals & insiders hold more shares of TRVN or ARDS?

Is TRVN or ARDS more profitable?

Does the media prefer TRVN or ARDS?

Which has better earnings and valuation, TRVN or ARDS?

Summary

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Which has better valuation & earnings, ARDS or NAVB?

Is ARDS or NAVB more profitable?

Does the media favor ARDS or NAVB?

Do insiders & institutionals have more ownership in ARDS or NAVB?

Which has more volatility and risk, ARDS or NAVB?

Summary

How does Aridis Pharmaceuticals compare to Smart for Life?

Does the media refer more to ARDS or SMFL?

Do insiders & institutionals hold more shares of ARDS or SMFL?

Which has more volatility & risk, ARDS or SMFL?

Which has preferable valuation & earnings, ARDS or SMFL?

Is ARDS or SMFL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDS vs. The Competition

Aridis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools